REVIVA PHARMACEUTICALS HOLDI (RVPH) Stock Income Statement
NASDAQ:RVPH - Nasdaq - US76152G1004 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-2-29) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 30.80M | 39.50M | 28.23M | 10.10M | 724.70K | |||
| Research and Development | 22.91M | 31.42M | 22.87M | 4.85M | 295.10K | |||
| Selling, General, and Administrative Expenses | 7.89M | 8.08M | 5.36M | 5.25M | 2.14M | |||
| Operating Income | -30.80M | -39.50M | -28.23M | -10.10M | -724.70K | |||
| Interest Income/Expense | 342.90K | 499.00K | 182.80K | -2.40K | 1.34M | |||
| Other Income/Expense | 556.70K | -239.20K | -194.70K | 1.59M | N/A | |||
| Income Before Taxes | -29.90M | -39.24M | -28.24M | -8.52M | 617.90K | |||
| Income Tax | 19.50K | 16.90K | 20.80K | 6.00K | 800.00 | |||
| Net Income | -29.92M | -39.26M | -28.26M | -8.52M | 617.90K | |||
| EBITDA | N/A | N/A | N/A | N/A | -724.10K | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.90 | -1.65 | -1.45 | -0.58 | 0.24 | |||
| Non GAAP EPS | -0.91 | -1.64 | -1.25 | -0.56 | N/A | |||
| Statistics | ||||||||
All data in USD